Thursday, March 26, 2015

Deals

Avalanche Biotechnologies (AAVL) Enters Exclusive License Agreement with University of Washington

March 25, 2015 · Leave a Comment 

  Avalanche Biotechnologies (Nasdaq: AAVL) today announced that it has entered into an exclusive license agreement with the University of Washington (UW) in Seattle to develop products based on Avalanche’s proprietary Ocular BioFactory™ Platform for the treatment of color vision deficiency (CVD), commonly known as red-green color blindness. Avalanche also announced today, outside of the scope of the license agreement, that Drs. Jay and Maureen Neitz, faculty in the UW’s Department of Ophthalmology and CVD experts, have joined its Scientific Advisory Board. They will be technical... [Read the full story]

Deal News

Avalanche Biotechnologies (AAVL) Enters Exclusive License Agreement with University of Washington

March 25, 2015 · Leave a Comment 

  Avalanche Biotechnologies (Nasdaq: AAVL) today announced that it has entered into an exclusive license agreement with the University of Washington (UW) in Seattle to develop products based on Avalanche’s proprietary Ocular BioFactory™ Platform for the treatment of color vision deficiency (CVD), commonly known as red-green color blindness. Avalanche also announced today, outside of the scope of the license agreement, that Drs. Jay and Maureen Neitz, faculty in the UW’s Department of Ophthalmology and CVD experts, have joined its Scientific Advisory Board. They will be technical... [Read the full story]

Legal

Semafone and Eckoh agree to settlement

March 19, 2015 · Leave a Comment 

  Guildford, Surrey, 19th March 2015 – Eckoh plc and Semafone® have agreed to a confidential settlement of their dispute over alleged infringement and invalidity of Semafone’s UK Patent (No. GB 2,473,376), to the mutual benefit of both parties.  Under the settlement, Semafone has granted a worldwide licence to their granted patents, trademarks and patent applications covering certain dual tone multi-frequency (“DTMF”) masking methods of taking secure payments over the phone, for the benefit of Eckoh, its customers and suppliers. In consideration of the licence, Eckoh... [Read the full story]

Bio

Biohaven enters into license deal for Catalent’s Zydis ODT technology

March 25, 2015 · Leave a Comment 

  Biohaven Pharmaceutical (Biohaven) has entered into an exclusive world-wide agreement with Catalent Pharma Solutions for its Zydis Orally Disintegrating Tablet (ODT) technology to be used in the development of Biohaven’s lead drug development candidate, BHV-0223. Canada-based Portage Biotech holds 54% equity of Biohaven, a privately-held biopharmaceutical firm engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system. Catalent’s Zydis technology is a freeze-dried, oral solid dosage form that disperses instantly... [Read the full story]

University Tech Transfer

Avalanche Biotechnologies (AAVL) Enters Exclusive License Agreement with University of Washington

March 25, 2015 · Leave a Comment 

  Avalanche Biotechnologies (Nasdaq: AAVL) today announced that it has entered into an exclusive license agreement with the University of Washington (UW) in Seattle to develop products based on Avalanche’s proprietary Ocular BioFactory™ Platform for the treatment of color vision deficiency (CVD), commonly known as red-green color blindness. Avalanche also announced today, outside of the scope of the license agreement, that Drs. Jay and Maureen Neitz, faculty in the UW’s Department of Ophthalmology and CVD experts, have joined its Scientific Advisory Board. They will be technical... [Read the full story]

People

IP Industry: we start here

March 8, 2015 · Leave a Comment 

In 2007, we set out to change the world of intellectual property, and how innovation and ideas were exchanged among IP owners and those that desired IP. We knew there were significant headwinds with an entrenched, decades-old ecosystem of long held beliefs about the “way things ought to be done” and who were we to come along and try to change things. None of this did anything to deter us; it drove us even harder. Not to gloat or brag, but many of the world’s LARGEST IP Owners and Transactors are now our customers- more on that in later posts.  They see the same future. IP Attorneys said... [Read the full story]

Deals

Avalanche Biotechnologies (AAVL) Enters Exclusive License Agreement with University of Washington

  Avalanche Biotechnologies (Nasdaq: AAVL) today announced that it has entered into an exclusive license agreement with the University of Washington (UW) in Seattle to develop products based on Avalanche’s proprietary Ocular BioFactory™ Platform for the treatment of color vision deficiency (CVD), commonly known as red-green color blindness. Avalanche... Read more of this article


Biohaven enters into license deal for Catalent’s Zydis ODT technology

  Biohaven Pharmaceutical (Biohaven) has entered into an exclusive world-wide agreement with Catalent Pharma Solutions for its Zydis Orally Disintegrating Tablet (ODT) technology to be used in the development of Biohaven’s lead drug development candidate, BHV-0223. Canada-based Portage Biotech holds 54% equity of Biohaven, a privately-held... Read more of this article


Photronics Enters into Strategic Supply and Technology License Agreements with Micron

  BROOKFIELD, Conn., Mar 24, 2015 (BUSINESS WIRE) — Photronics, Inc. PLAB, -1.26% a worldwide leader in supplying innovative imaging technology solutions for the global electronics industry, announced today that it has entered into strategic supply and technology license agreements with Micron Technology, Inc. MU, +0.26% whereby Photronics... Read more of this article


Scottish partnership to develop photonics techniques

  Scotland-based M Squared Lasers is partnering with the University of St Andrews to develop a new range of photonics and laser-based technologies designed to help in the detection and treatment of conditions such as cancer and Alzheimer’s disease. The newly-signed IPR Technology Transfer Agreement covers a broad portfolio of more than 100 patents,... Read more of this article


Eli Lilly and Company (NYSE:LLY) Will Collaborate

  Eli Lilly and Company (NYSE:LLY) [Trend Analysis] as well as Innovent Biologics, Inc. reported that the firms will collaborate to support the development and potential commercialization of at least three cancer treatments over the next decade. Innovent is a leading biopharmaceutical firm in China focused on the development and manufacturing of... Read more of this article


Ubiquity Licenses to Sprocket

  IRVINE, Calif., March 24, 2015 /PRNewswire/ — Ubiquity, Inc. (OTCQB: UBIQ) (“Ubiquity” or the “Company”), a technology development and licensing company that holds an extensive portfolio of patents across multiple technology market verticals, announced today it has entered into a license agreement with its investment... Read more of this article


Portage’s Biohaven enters into exclusive license agreement with Catalent

  TORONTO, March 24, 2015 /PRNewswire/ – Portage Biotech Inc. (“Portage”) (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that Biohaven Pharmaceutical Holding Company Limited (Biohaven), which Portage holds 54% equity, has entered into an exclusive world-wide agreement with Catalent Pharma Solutions... Read more of this article


Thermo Fisher Licenses ToolGen’s Gene Editing IP

  AsianScientist (Mar. 24, 2015) – ToolGen, Inc., a Korean biotechnology company with a focus in the genome editing space, has entered an agreement to license its CRISPR/Cas9 intellectual property portfolio to Thermo Fisher Scientific. Thermo Fisher will utilize the technology to develop and market new CRISPR reagent kits, bringing new tools... Read more of this article


Rambus Enters Patent License Agreement with IBM

  Rambus (NASDAQ: RMBS) announced it has signed both patent and technology license agreements with IBM. The patent license agreement authorizes IBM to integrate Rambus memory controller and serial link interface technologies. The technology license agreement will have Rambus develop and deliver high-performance memory interface design IP to enhance... Read more of this article


ISA Scientific, Yissum, Hadasit and the Kennedy Trust for Rheumatology Research to Collaborate

JERUSALEM–(BUSINESS WIRE)–Yissum Research Development Company Ltd. (Yissum), the technology transfer company of the Hebrew University of Jerusalem, Hadasit Ltd. (Hadasit), the technology transfer company of the Hadassah Medical Organization in Jerusalem, and the Kennedy Trust for Rheumatology Research (KIR) in the United Kingdom announced... Read more of this article


More Posts From Deals

Legal

Semafone and Eckoh agree to settlement

  Guildford, Surrey, 19th March 2015 – Eckoh plc and Semafone® have agreed... 


Iteris, Wavetronix Settle Patent Infringement Litigation

  SANTA ANA, Calif.–Iteris, Inc. (NYSE MKT: ITI), a leader in providing... 


More Posts From Legal

University Tech Transfer

Avalanche Biotechnologies (AAVL) Enters Exclusive License Agreement with University of Washington

  Avalanche Biotechnologies (Nasdaq: AAVL) today announced that it has entered... 


Scottish partnership to develop photonics techniques

  Scotland-based M Squared Lasers is partnering with the University of St Andrews... 


More Posts From University Tech Transfer